Nick Pizzie

CFO Nick Pizzie sold 33,000 AXSM shares at $240.09 (total $7.9M) under 10b5-1 plan; holds 42,867 shares post-sale plus 72,000 stock options.

CFO Nick Pizzie sold 33,000 shares (33.0K shares) of Axsome for $7,922,970.00 (total value), reducing his non-derivative holdings from 75,867 to 42,867 shares, a reduction of -43.5%. This transaction was executed under a pre-arranged 10b5-1 trading plan and therefore was scheduled, not discretionary. Notably, prior sales by this insider at AXSM show mixed near-term outcomes: his January 2026 sale returned -2.2% at 30 days, while his two February 2025 sales returned -7.0% and -6.1% at 30 days respectively. The company remains unprofitable (net income of $-64,542,000.00 for the latest quarter) despite strong revenue growth of +65.6% year-over-year, which presents a context of expansion without current profitability. The insider retains substantial derivative holdings of 72,000 stock options, indicating continued equity exposure to the company.

CFO Pizzie Nick sold 12,000 AXSM shares at $187.92 (Jan 22) for $2.3M; stock now -1.7% from 52-week high

CFO Pizzie Nick sold 12,000 shares (22.0% reduction in holdings) at $187.92, near the stock's 52-week high of $189.10, while Axsome trades as a high-growth but unprofitable biotech with quarterly revenue of $171.0M, full-year net income of $-47.2M, and annual growth of 42.5%. His prior two sales at this ticker (Feb 2025) were both followed by 90-day declines of -18.2% and -20.2%, establishing a pattern of well-timed exits at this specific stock. The timing of this sale—near 52-week highs and following a 21.0% 30-day rally—warrants attention relative to the company's ongoing unprofitability and his demonstrated ability to exit before subsequent weakness.

CFO Nick Pizzie sold 15,000 AXSM shares at $129.86–$131.07 for $1,951,530.00; 52-week high is $132.20.

Pizzie Nick, CFO of Axsome Therapeutics, executed 2 separate sales totaling 15,000 shares for $1,951,530.00 at an average price of $130.10, reducing his holdings by 26.2% to 42,187 shares post-transaction. The current price of $131.15 is 0.8% below the 52-week high of $132.20, and the stock has gained 39.9% over the prior 30 days and 40.8% over the prior 90 days. The company's latest quarterly revenue reached $104,762,000.00, supporting 440.8% annual revenue growth, but the firm remains unprofitable with a net income of $-64,602,000.00 and a full-year loss. The sale occurred at prices very near all-time highs in a sharp near-term rally, against the backdrop of sustained unprofitability despite exceptional top-line expansion.